查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576813

生殖器皰疹治療市場：按類型、臨床試驗、給藥途徑、藥物類別、最終用戶、年齡層、患者性別 - 全球預測 2025-2030

Genital Herpes Treatment Market by Type (Antiviral Medications, Supplements, Topical Creams/Ointments), Clinical Trials (Phase I, Phase II, Phase III), Route Of Administration, Drug Class, End User, Age Group, Patient Gender - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

生殖器皰疹治療市場2023年估值為20.8億美元，預計到2024年將達到21.7億美元，複合年成長率為4.80%，預計到2030年將達到29億美元。

生殖器皰疹治療市場的定義是旨在控制症狀和減少單純皰疹病毒感染疾病爆發的治療藥物。該系列包括阿昔洛韋、伐昔洛韋和泛昔洛韋等抗病毒藥物，這些藥物對於改善患者的生活品質至關重要。這種疾病的慢性性質及其流行性強調了對這些治療的需求，這繼續刺激了對處方藥和非處方藥的需求。最終用途包括醫院、專科診所和零售藥局。影響市場的主要成長要素包括人們對診斷的認知和關注的提高、診斷技術的發展以及更有效的治療方法和潛在疫苗的研發。個人化醫療和長期抑制治療的發展商機不斷擴大，技術創新之路也日漸清晰。然而，社會恥辱、患者依從性問題以及與替代療法的競爭等限制帶來了重大挑戰。監管障礙和不斷上升的研發成本將進一步拖累市場擴張。也就是說，利用遠端醫療進行遠距離診斷和治療，並與策略夥伴關係推進抗病毒藥物開發研究，可以創造重大的商業前景。最有前景的技術創新領域包括CRISPR-Cas9基因編輯和免疫療法，它們有潛力開發根治性方法。競爭格局的特點是大型製藥企業大力投資臨床試驗和探索性研究以獲取市場佔有率。基於這些見解，鼓勵公司專注於加強患者教育舉措、降低成本以提高可及性，並建立策略合作夥伴關係以推動創新和市場滲透。這樣做將促進這個充滿活力且不斷發展的行業的成長並產生可觀的收益流。

主要市場統計
基準年[2023] 20.8億美元
預測年份 [2024] 21.7億美元
預測年份 [2030] 29億美元
複合年成長率（%） 4.80%

市場動態：快速發展的生殖器皰疹治療市場的關鍵市場洞察

供需的動態交互作用正在改變生殖器皰疹治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 早期核准新的生殖器皰疹治療方法的法規結構的演變
    • 社群媒體和數位平台對傳播生殖器皰疹治療方案認知的影響
    • 抗病毒藥物抗藥性的增加需要開發新的治療方法
    • 個人化治療對生殖器皰疹患者的重要性日益增加
  • 市場限制因素
    • 由於病毒的複雜性，開發生殖器皰疹疫苗面臨挑戰
  • 市場機會
    • 利用先進的給藥系統提高療效和病人依從性
    • 將全面的性健康教育納入生殖器皰疹治療計劃
    • 擴大基因組研究，為生殖器皰疹患者開發個人化治療方法
  • 市場挑戰
    • 與生殖器皰疹相關的恥辱和恥辱導致診斷和治療的延誤

波特五力：開拓生殖器皰疹治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生殖器皰疹治療市場的外部影響

外部宏觀環境因素在塑造生殖器皰疹治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生殖器皰疹治療市場的競爭狀況

生殖器皰疹治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生殖器皰疹治療市場供應商的績效評估

FPNV定位矩陣是評估生殖器皰疹治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了生殖器皰疹治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，生殖器皰疹治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 快速核准生殖器皰疹新療法的法規結構的演變
      • 社群媒體和數位平台對傳播生殖器皰疹治療方案認知的影響
      • 抗病毒藥物抗藥性的蔓延需要開發新的治療方法
      • 個人化醫療對於生殖器皰疹患者的客製化治療越來越重要
    • 抑制因素
      • 由於病毒的複雜性，生殖器皰疹疫苗開發面臨挑戰
    • 機會
      • 利用先進的給藥系統提高生殖器皰疹治療效果和患者依從性
      • 將全面的性教育納入您的生殖器皰疹治療計劃
      • 擴大基因組研究，為生殖器皰疹患者開發個人化治療方案
    • 任務
      • 與生殖器皰疹相關的恥辱和恥辱導致診斷和治療的延誤
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 生殖器皰疹治療市場：依類型

  • 抗病毒藥物
    • 阿昔洛韋
    • 泛昔洛韋
    • 伐昔洛韋
  • 補充品
  • 外用乳霜/軟膏

第7章臨床試驗的生殖器皰疹治療市場

  • 第一階段
  • 第二階段
  • 第三階段

第8章 生殖器皰疹治療市場：依給藥途徑

  • 可注射的
  • 口服
  • 話題

第9章按藥物類別分類的生殖器皰疹治療市場

  • 抗病毒藥
  • 免疫調節劑

第 10 章 生殖器皰疹治療市場：依最終使用者分類

  • 診所
  • 家庭護理設置
  • 醫院
  • 藥局

第11章生殖器皰疹治療市場：依年齡層

  • 成人
  • 老年醫學
  • 小兒科

第12章生殖器皰疹治療市場患者性別

  • 女士
  • 男人

第13章北美和南美洲生殖器皰疹治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太地區生殖器皰疹治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章 歐洲、中東和非洲生殖器皰疹治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0410

The Genital Herpes Treatment Market was valued at USD 2.08 billion in 2023, expected to reach USD 2.17 billion in 2024, and is projected to grow at a CAGR of 4.80%, to USD 2.90 billion by 2030.

The market for genital herpes treatment is defined by therapies aimed at managing symptoms and reducing outbreaks of herpes simplex virus infections. This scope encompasses antiviral medications, such as acyclovir, valacyclovir, and famciclovir, which are essential for improving patient quality of life. The necessity of these treatments is underscored by the chronic nature of the condition and its prevalence, which continues to stimulate demand for both prescription medications and over-the-counter options. Application primarily targets disease management and transmission reduction, while end-use includes hospitals, specialty clinics, and retail pharmacies. Key growth factors influencing the market involve increased awareness and diagnosis, technological advancements in diagnostics, and a growing focus on research and development for more effective therapies and potential vaccines. Opportunities are surfacing in personalized medicine and the development of long-term suppressive therapies, presenting avenues for innovation. However, limitations such as social stigma, patient adherence issues, and competition from alternative therapies pose significant challenges. Regulatory hurdles and high costs of R&D further strain market expansion. Nonetheless, leveraging telehealth for remote diagnosis and treatment, along with strategic partnerships for advancing research in antiviral drug development, can create substantial business prospects. The most promising areas for innovation involve exploring CRISPR-Cas9 gene editing and immunotherapy as potential forays to develop curative treatments. The genital herpes treatment market is characterized by a competitive landscape with major pharmaceutical companies investing heavily in clinical trials and exploratory research to capture market share. Building on these insights, businesses are advised to focus on enhancing patient education initiatives, reducing costs to improve accessibility, and developing strategic alliances to boost innovation and market penetration. This will foster growth and generate substantial revenue streams within this dynamic and continuously evolving sector.

KEY MARKET STATISTICS
Base Year [2023] USD 2.08 billion
Estimated Year [2024] USD 2.17 billion
Forecast Year [2030] USD 2.90 billion
CAGR (%) 4.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genital Herpes Treatment Market

The Genital Herpes Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Evolving regulatory frameworks aimed at fast-tracking approvals of new genital herpes treatments
    • The influence of social media and digital platforms in spreading awareness about genital herpes treatment options
    • Rising prevalence of antiviral resistance necessitating the development of new treatment modalities
    • Growing importance of personalized medicine in tailoring treatments for genital herpes patients
  • Market Restraints
    • Challenges in developing a vaccine for genital herpes due to the complex nature of the virus
  • Market Opportunities
    • Leveraging advanced drug delivery systems to improve genital herpes treatment efficacy and patient adherence
    • Integrating comprehensive sexual health education into treatment plans for genital herpes
    • Expanding genomic research to develop personalized treatment options for genital herpes patients
  • Market Challenges
    • Stigma and embarrassment associated with genital herpes leading to delayed diagnosis or treatment

Porter's Five Forces: A Strategic Tool for Navigating the Genital Herpes Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genital Herpes Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genital Herpes Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genital Herpes Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genital Herpes Treatment Market

A detailed market share analysis in the Genital Herpes Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genital Herpes Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genital Herpes Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genital Herpes Treatment Market

A strategic analysis of the Genital Herpes Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genital Herpes Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Mylan, Novartis, Pfizer, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Vertex Pharmaceuticals, and ViiV Healthcare.

Market Segmentation & Coverage

This research report categorizes the Genital Herpes Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antiviral Medications, Supplements, and Topical Creams/Ointments. The Antiviral Medications is further studied across Acyclovir, Famciclovir, and Valacyclovir.
  • Based on Clinical Trials, market is studied across Phase I, Phase II, and Phase III.
  • Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Drug Class, market is studied across Antiviral and Immune Modulators.
  • Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Pharmacies.
  • Based on Age Group, market is studied across Adults, Geriatrics, and Pediatrics.
  • Based on Patient Gender, market is studied across Female and Male.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Evolving regulatory frameworks aimed at fast-tracking approvals of new genital herpes treatments
      • 5.1.1.2. The influence of social media and digital platforms in spreading awareness about genital herpes treatment options
      • 5.1.1.3. Rising prevalence of antiviral resistance necessitating the development of new treatment modalities
      • 5.1.1.4. Growing importance of personalized medicine in tailoring treatments for genital herpes patients
    • 5.1.2. Restraints
      • 5.1.2.1. Challenges in developing a vaccine for genital herpes due to the complex nature of the virus
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging advanced drug delivery systems to improve genital herpes treatment efficacy and patient adherence
      • 5.1.3.2. Integrating comprehensive sexual health education into treatment plans for genital herpes
      • 5.1.3.3. Expanding genomic research to develop personalized treatment options for genital herpes patients
    • 5.1.4. Challenges
      • 5.1.4.1. Stigma and embarrassment associated with genital herpes leading to delayed diagnosis or treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genital Herpes Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Antiviral Medications
    • 6.2.1. Acyclovir
    • 6.2.2. Famciclovir
    • 6.2.3. Valacyclovir
  • 6.3. Supplements
  • 6.4. Topical Creams/Ointments

7. Genital Herpes Treatment Market, by Clinical Trials

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III

8. Genital Herpes Treatment Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Genital Herpes Treatment Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Antiviral
  • 9.3. Immune Modulators

10. Genital Herpes Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare Settings
  • 10.4. Hospitals
  • 10.5. Pharmacies

11. Genital Herpes Treatment Market, by Age Group

  • 11.1. Introduction
  • 11.2. Adults
  • 11.3. Geriatrics
  • 11.4. Pediatrics

12. Genital Herpes Treatment Market, by Patient Gender

  • 12.1. Introduction
  • 12.2. Female
  • 12.3. Male

13. Americas Genital Herpes Treatment Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Genital Herpes Treatment Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Genital Herpes Treatment Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Biogen
  • 6. Bristol-Myers Squibb
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline
  • 11. Johnson & Johnson
  • 12. Merck & Co.
  • 13. Mylan
  • 14. Novartis
  • 15. Pfizer
  • 16. Sanofi
  • 17. Takeda Pharmaceutical
  • 18. Teva Pharmaceutical Industries
  • 19. Vertex Pharmaceuticals
  • 20. ViiV Healthcare

LIST OF FIGURES

  • FIGURE 1. GENITAL HERPES TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GENITAL HERPES TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. GENITAL HERPES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. GENITAL HERPES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENITAL HERPES TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENITAL HERPES TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 322. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN GENITAL HERPES TREATMENT MARKET SI